Growth in Disorders of Adrenal Hyperfunction

2002 ◽  
Vol 58 (1) ◽  
pp. 39-43 ◽  
Author(s):  
M.O. Savage ◽  
S. Scommegna ◽  
P.V. Carroll ◽  
J.T.F. Ho ◽  
J.P. Monson ◽  
...  
Keyword(s):  
Adrenal Hyperfunction

ATYPICAL ADRENAL HYPERFUNCTION: IN VIVO STUDIES AND INCUBATIONS OF ADRENAL TISSUE WITH 4-14C PROGESTERONE

1968 ◽  
Vol 58 (3_Suppl) ◽  
pp. S5-S34
Author(s):  
Joseph W. Goldzieher ◽  
Leonard R. Axelrod ◽  
Arthur S. Weissbein
Keyword(s):  
Urinary Excretion ◽  
Clinical Features ◽  
In Vivo Studies ◽  
Acth Stimulation ◽  
Adrenal Tissue ◽  
Adrenal Hyperfunction

ABSTRACT Six women with atypical forms of adrenal cortical hyperfunction were studied by means of urinary excretion of 17-ketosteroids and 17-hydroxycorticoids and their response to ACTH stimulation and corticosteroid suppression. Unusual responses were observed, particularly with respect to the independence of 17-KS and 17-OHCS excretion. The adrenals of 3 patients were anatomically normal whereas the others showed hyperplasia. Minced adrenal tissue was incubated with 4-14C progesterone and the metabolites isolated and definitively identified. The pattern of biosynthesized corticosteroids showed great variation, and in some instances clarified certain clinical features. The pattern of certain C19-metabolites could not be studied adequately because of the use of a Δ4 rather than a Δ5 substrate.

Suppression of tumorous adrenal hyperfunction by aminoglutethimide

Metabolism ◽  
1967 ◽  
Vol 16 (4) ◽  
pp. 374-377 ◽  
Author(s):  
Renata P. Smilo ◽  
Jerry M. Earll ◽  
Peter H. Forsham
Keyword(s):  
Adrenal Hyperfunction

Ovarian Tumor, Precocious Puberty, and Adrenal Hyperfunction

1959 ◽  
Vol 78 (4) ◽  
pp. 821-824
Author(s):  
Juan B. Scarpa ◽  
Hugo Beheran ◽  
Adolfo A. Raices ◽  
Grato E. Bur
Keyword(s):  
Precocious Puberty ◽  
Ovarian Tumor ◽  
Adrenal Hyperfunction

Androgenic Adrenal Hyperfunction in Acromegaly

1964 ◽  
Vol 271 (23) ◽  
pp. 1189-1194 ◽  
Author(s):  
Nicholas Y. Lim ◽  
Joseph F. Dingman
Keyword(s):  
Adrenal Hyperfunction

ERFOLGREICHE BEHANDLUNG EINES FALLES VON CUSHING-SYNDROM MIT o,p-DDD

1962 ◽  
Vol 40 (3) ◽  
pp. 332-348 ◽  
Author(s):  
Georg Geyer
Keyword(s):  
Complete Remission ◽  
Liver Function ◽  
Total Dose ◽  
Needle Biopsy ◽  
Liver Function Tests ◽  
Cushing's Syndrome ◽  
Intermittent Administration ◽  
Urinary Steroids ◽  
Function Tests ◽  
Adrenal Hyperfunction

ABSTRACT o,p-DDD was tried as an adrenal inhibitor in a patient with Cushing's syndrome due to non-tumorous adrenal hyperfunction. Administration of a total dose of 382 grams of o,p-DDD during a period of 105 days resulted in a complete remission of the previously existing symptoms of hypercorticism. The elevated excretion of urinary steroids decreased to normal during the course of o,p-DDD administration. Symptoms of hypoadrenalism did not develop during the four months of treatment. Remission in that patient is being maintained by intermittent administration of o,p-DDD Though liver function tests remained normal throughout the course of treatment marked fatty changes of the liver were dedected in material obtained by needle biopsy. As a further symptom of toxicity of o,p-DDD anorexia was observed.

scholarly journals Risk Factors and Long-Term Follow-Up of Adrenal Incidentalomas1

1999 ◽  
Vol 84 (2) ◽  
pp. 520-526
Author(s):  
Luisa Barzon ◽  
Carla Scaroni ◽  
Nicoletta Sonino ◽  
Francesco Fallo ◽  
Agostino Paoletta ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adrenal Mass ◽  
Statistical Significance ◽  
Adrenal Incidentaloma ◽  
Long Term Follow Up ◽  
Mass Size ◽  
Obesity Hypertension ◽  
Cumulative Risks ◽  
Adrenal Hyperfunction

The natural course of adrenal incidentalomas and the risk that such lesions evolve toward hormonal hypersecretion or malignancy are still under evaluation. Of 246 consecutive patients with adrenal incidentaloma studied at our institution in the last 15 yr, 91 underwent surgery. Of the remaining patients, a group of 75 (52 females and 23 males; median age, 56 yr; range, 19–77 yr) with incidentally discovered asymptomatic adrenal masses (60 unilateral and 15 bilateral; median diameter, 2.5 cm; range, 1.0–5.6) was enrolled in an endocrine and morphological follow-up of at least 2 yr after diagnosis (median, 4 yr; range, 2–10). During follow-up, no patients developed malignancy; 9 showed mass enlargement, with appearance of a new mass in the contralateral gland in 2; 3 developed adrenal hyperfunction (overt Cushing’s syndrome in 2, nonclinical hypercortisolism in 1); and 3 showed adrenal mass enlargement associated with adrenal hyperfunction (nonclinical hypercortisolism in 2, pheochromocytoma in 1). The estimated cumulative risks to develop mass enlargement and hyperfunction were 8% and 4%, respectively, after 1 yr, 18% and 9.5% after 5 yr, and 22.8% and 9.5% after 10 yr. Nine risk factors for adrenal mass enlargement or hyperfunction were arbitrarily selected and evaluated: sex, age, presence of obesity, hypertension, diabetes, abnormal endocrine tests, mass size, mass location, and scintigraphic uptake pattern. Three of them attained statistical significance: mass size of 3 cm or more at diagnosis and exclusive radiocholesterol uptake by the mass at scintigraphy had relevance for the occurrence of adrenal hyperfunction, whereas the presence of endocrine test abnormalities at diagnosis had predictive value for mass enlargement. It is concluded that subtle hormonal abnormalities are risk factors for mass size increase, which is not a sign of malignant transformation. Both mass size of 3 cm or more at diagnosis and exclusive radiocholesterol uptake, indicating higher risks of hyperfunction, should be considered to plan a more thorough endocrine follow-up.

STEROID SYNTHESIS IN A HUMAN VIRILISING ADRENAL CARCINOMA – SOME UNUSUAL FEATURES

1970 ◽  
Vol 65 (1) ◽  
pp. 133-147 ◽  
Author(s):  
E. H. D. Cameron ◽  
J. Hammerstein ◽  
D. Jones ◽  
S. Morris ◽  
K. Griffiths
Keyword(s):  
Tennis Ball ◽  
Adrenal Carcinoma ◽  
Steroid Synthesis ◽  
Ball Size ◽  
Steroid Analysis ◽  
History Of ◽  
Suppression Test ◽  
Dexamethasone Suppression ◽  
Adrenal Hyperfunction

ABSTRACT A patient presenting at the Universitäts-Frauenklinik, Berlin with a long history of increasing hirsutism and virilism provided an opportunity to study an unusual form of adrenal hyperfunction. It was found that she behaved abnormally with respect to the dexamethasone suppression test since her highly elevated 17-oxosteroid output further increased by approximately 400% with 8 mg/day dosage. Her basal 17-hydroxycorticosteroid output was elevated but not grossly so, nor did she exhibit the usual signs of Cushing's syndrome of weight increase and florid complexion. At operation a »tennis ball« size adrenal carcinoma was removed from the left side. Incubation studies were performed on sliced tumour tissue with substrates [1-14C] acetate, [7α-3H] pregnenolone, [4-14C] progesterone and [4-14C] androst-4-ene-3,17-dione. The frozen incubation mixtures were subsequently flown to Cardiff for steroid analysis by reverse radioisotope dilution techniques. The combined urinary and incubation results suggested that, in vivo, the tumour secreted DHA and not DHA sulphate and that there appeared to be a considerable deficiency of DHA-3β-hydroxysteroid dehydrogenase/Δ5−4-isomerase and of DHA-3β-sulphokinase activities although the steroid-11β-hydroxylase, 17α-hydroxylase and 21-hydroxylase activities seemed unimpaired.

Sign in / Sign up

Export Citation Format

Share Document